Oncotarget

Research Papers:

Systematic analysis of gene expression alterations and clinical outcomes of adenylate cyclase-associated protein in cancer

Shuanshuan Xie, Changxing Shen, Min Tan, Ming Li, Xiaolian Song and Changhui Wang _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:27216-27239. https://doi.org/10.18632/oncotarget.16111

Metrics: PDF 1083 views  |   HTML 1564 views  |   ?  


Abstract

Shuanshuan Xie1, Changxing Shen1, Min Tan1, Ming Li1, Xiaolian Song1, Changhui Wang1

1Department of Respiratory Medicine, Shanghai Tenth People's Hospital, Tongji University, Shanghai 200072, China

Correspondence to:

Changhui Wang, email: wang-chang-hui@hotmail.com

Keywords: adenylate cyclase-associated protein, copy number alteration, mutation, overall survival

Received: July 07, 2016     Accepted: February 20, 2017     Published: March 10, 2017

ABSTRACT

Adenylate Cyclase-associated protein (CAP) is an evolutionarily conserved protein that regulates actin dynamics. Our previous study indicates that CAP1 is overexpressed in NSCLC tissues and correlated with poor clinical outcomes, but CAP1 in HeLa cells actually inhibited migration and invasion, the role of CAP was discrepancy in different cancer types. The present study aims to determine whether CAP can serve as a prognostic marker in human cancers. The CAP expression was assessed using Oncomine database to determine the gene alteration during carcinogenesis, the copy number alteration, or mutations of CAP using cBioPortal, International Cancer Genome Consortium, and Tumorscape database investigated, and the association between CAP expression and the survival of cancer patient using Kaplan-Meier plotter and PrognoScan database evaluated. Therefore, the functional correlation between CAP expression and cancer phenotypes can be established; wherein CAP might serve as a diagnostic marker or therapeutic target for certain types of cancers.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 16111